Yan Leyfman: Remarkable Results with CAR-NK Cells – Now in Systemic Sclerosis
CAR-NK cells are in the spotlight once again. Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on X about a paper by Xiaobing Wang et al. published in Cell:
“First-in-Human Breakthrough.
Researchers have used iPSC-derived dual-targeting CAR-NK cells (QN-139b) to treat a patient with severe, refractory systemic sclerosis – with remarkable results:
- Dual targeting CD19 + BCMA to eliminate pathogenic B cells
- Minimal toxicity, no structural chromosomal abnormalities
- Reversal of fibrosis and restoration of skin and vascular structure
- Reduced autoantibodies and shift toward naïve B cell phenotypes
- Suppressed inflammation and promoted tissue regeneration
This could mark a new frontier in immune-modulatory therapy for autoimmune disease – combining precision targeting with regenerative potential.”
Title: An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
Authors: Xiaobing Wang, Yi Zhang, Yi Jin, Lie Dai, Yanan Yue, Jiapan Hu, Xin Liu, Kun Pang, Songying Ye, Yue Chen, Wenjing Ye, Xiaofei Shi, Xin Ma, Lehang Guo, Yanfang Liu, Na Ta, Xiaofang Zhu, Li Lin, Jiazheng Wang, Ran Yan, Ping Wang, Xiaobin Song, Yixuan Zhou, Lina Zhou, Qing Wang, Tongxiang Guan, Ting Li, Ling Zhou, Weihua Pan, Yanran He, Xin Wu, Yingyong Xu, Luhan Yang, Huji Xu
You can read the Full Article on Cell.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023